SEC Company Response from Sanofi (SNY, SNYNF) (CIK 0001121404) (SNY) — Sep 27, 2005
Sanofi (SNY, SNYNF) (CIK 0001121404)
Date: Sept. 27, 2005 · CIK: 0001121404 · Accession: 0000898822-05-001228
AI Filing Summary & Sentiment
File numbers found in text: 001-31368
Referenced dates: September 16, 2005
Letter
September 27, 2005 VIA EDGAR Mr. James Peklenk Staff Accountant Division of Corporation Finance Securities and Exchange Commission 450 Fifth Street, N.W., MailStop 6010 Washington, D.C. 20549
Re: Sanofi-Aventis Form 20-F for Fiscal Year Ended December 31, 2004 Filed April 11, 2005 File No. 001-31368 -------------------------------------------------
Dear Mr. Peklenk:
This is a follow up to our telephone conversation last week regarding the Staff's comment letter dated September 16, 2005 addressed to Mr. Jean-Claude Leroy, Chief Financial Officer of Sanofi-Aventis. As we discussed, this firm acts as special United States counsel to Sanofi-Aventis and this letter is being sent on their behalf.
This letter is to confirm that, as we discussed, Sanofi-Aventis is in the process of gathering information responsive to the Staff's September 16, 2005 comment letter and intends to respond to the Staff's comment letter in mid-October.
Please do not hesitate to contact me at (212) 403-1309 if you have any questions.
Very truly yours,
/s/ David A. Katz
Show Raw Text
<DOCUMENT>
<TYPE>CORRESP
<SEQUENCE>1
<FILENAME>filename1.txt
<TEXT>
[Letterhead of Wachtell, Lipton, Rosen & Katz]
September 27, 2005
VIA EDGAR
Mr. James Peklenk
Staff Accountant
Division of Corporation Finance
Securities and Exchange Commission
450 Fifth Street, N.W., MailStop 6010
Washington, D.C. 20549
Re: Sanofi-Aventis
Form 20-F for Fiscal Year Ended December 31, 2004
Filed April 11, 2005
File No. 001-31368
-------------------------------------------------
Dear Mr. Peklenk:
This is a follow up to our telephone conversation last week
regarding the Staff's comment letter dated September 16, 2005 addressed to Mr.
Jean-Claude Leroy, Chief Financial Officer of Sanofi-Aventis. As we discussed,
this firm acts as special United States counsel to Sanofi-Aventis and this
letter is being sent on their behalf.
This letter is to confirm that, as we discussed, Sanofi-Aventis
is in the process of gathering information responsive to the Staff's September
16, 2005 comment letter and intends to respond to the Staff's comment letter in
mid-October.
Please do not hesitate to contact me at (212) 403-1309 if you
have any questions.
Very truly yours,
/s/ David A. Katz
David A. Katz
cc: Jean-Claude Leroy
John Felitti
Peter Nurczynski
</TEXT>
</DOCUMENT>